Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report.

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis. Herein, we described the case of an 87-year-old woman treated with Janus kinase inhibitor (JAKi). Chest computed tomography revealed increased honeycombing; she was administered nitedanib while continuing RA treatment. The combination treatment (JAKi and nintedanib) controlled the RA disease activity, without ILD deterioration. This case shows the potential of combination treatment with JAKi and nintedanib for prevention of worsening of disease activity in RA and ILD.